The global life sciences and R&D sector demonstrates resilient, long-term growth, supported by demographic shifts, rising healthcare demand and technological advancements. For institutional investors, this growth has historically translated into a concentration of capital in North America and Europe, where mature ecosystems offer scale and familiarity.
Asia Pacific presents a different proposition, as its life sciences and R&D sector trajectory is increasingly shaped by factors that warrant closer scrutiny. The region’s momentum is real — growth is driven not only by ageing populations and escalating healthcare expenditure, but also by deliberate national strategies to build research capability, strengthen innovation and reduce reliance on external supply chains. Asia Pacific has a significantly lower proportion of funding coming from the venture capital sector, which leads to less volatility in demand resulting from the venture capital cycle and tenants in the sp
